Bipolar I Disorder

Also known as: Bipolar 1 disorder

DrugDrug NameDrug Description
DB01238AripiprazoleAripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
DB00555LamotrigineLamotrigine is an antiepileptic drug belonging in the phenyltriazine class used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. In the US, lamotrigine is available as oral tablets under the market name Lamictal. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. While lamotrigine is primarily indicated for epilepsy and bipolar disorders, there is evidence that it could have some clinical efficacy in some neuropathic pain states. Lamotrigine is also used as an off-label drug in treating other neurologic and psychiatric pathologies like borderline personality disorder [A31737]. The exact mechanism of action of lamotrigine is not fully elucidated, as it may have multiple cellular actions that contribute to its broad clinical efficacy.
DB01224QuetiapineQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
DrugDrug NameTargetType
DB01238AripiprazoleD(2) dopamine receptortarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Atarget
DB01238Aripiprazole5-hydroxytryptamine receptor 2Atarget
DB01238AripiprazoleCytochrome P450 3A4enzyme
DB01238AripiprazoleCytochrome P450 2D6enzyme
DB01238Aripiprazole5-hydroxytryptamine receptor 1Btarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Dtarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Etarget
DB01238AripiprazoleD(1A) dopamine receptortarget
DB01238AripiprazoleD(1B) dopamine receptortarget
DB01238AripiprazoleD(3) dopamine receptortarget
DB01238AripiprazoleD(4) dopamine receptortarget
DB01238Aripiprazole5-hydroxytryptamine receptor 2Ctarget
DB01238Aripiprazole5-hydroxytryptamine receptor 3Atarget
DB01238Aripiprazole5-hydroxytryptamine receptor 6target
DB01238Aripiprazole5-hydroxytryptamine receptor 7target
DB01238AripiprazoleHistamine H1 receptortarget
DB01238AripiprazoleAlpha-1A adrenergic receptortarget
DB01238AripiprazoleAlpha-1B adrenergic receptortarget
DB01238AripiprazoleAlpha-2A adrenergic receptortarget
DB01238AripiprazoleAlpha-2B adrenergic receptortarget
DB01238AripiprazoleAlpha-2C adrenergic receptortarget
DB01238AripiprazoleMuscarinic acetylcholine receptor M1target
DB01238AripiprazoleMuscarinic acetylcholine receptor M2target
DB01238AripiprazoleMuscarinic acetylcholine receptor M3target
DB01238AripiprazoleMuscarinic acetylcholine receptor M4target
DB01238AripiprazoleMuscarinic acetylcholine receptor M5target
DB01238AripiprazoleCytochrome P450 3A5enzyme
DB01238AripiprazoleCytochrome P450 3A7enzyme
DB00555LamotrigineSodium channel protein type 2 subunit alphatarget
DB00555LamotrigineUDP-glucuronosyltransferase 1-4enzyme
DB00555LamotrigineMultidrug resistance protein 1transporter
DB00555LamotrigineUDP-glucuronosyltransferase 1-3enzyme
DB00555LamotrigineDihydrofolate reductaseenzyme
DB00555Lamotrigine5-hydroxytryptamine receptor 3Atarget
DB00555LamotrigineVoltage-dependent R-type calcium channel subunit alpha-1Etarget
DB00555LamotrigineAdenosine receptor A1target
DB00555LamotrigineAdenosine receptor A2atarget
DB00555LamotrigineAlpha-1A adrenergic receptortarget
DB00555LamotrigineAlpha-2A adrenergic receptortarget
DB00555LamotrigineBeta-1 adrenergic receptortarget
DB00555LamotrigineD(1) dopamine receptortarget
DB00555LamotrigineD(2) dopamine receptortarget
DB00555LamotrigineGABA-A receptor (anion channel)target
DB00555LamotrigineGABA-A receptor (benzodiazepine site)target
DB00555LamotrigineHistamine H1 receptortarget
DB00555LamotrigineKappa-type opioid receptortarget
DB00555LamotrigineMuscarinic acetylcholine receptortarget
DB00555Lamotrigine5-hydroxytryptamine receptor 2Atarget
DB00555LamotrigineUDP-glucuronosyltransferase 1-1enzyme
DB00555LamotrigineSolute carrier family 22 member 2transporter
DB01224Quetiapine5-hydroxytryptamine receptor 2Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 2Ctarget
DB01224QuetiapineD(2) dopamine receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Atarget
DB01224QuetiapineHistamine H1 receptortarget
DB01224QuetiapineCytochrome P450 3A4enzyme
DB01224QuetiapineAlpha-1A adrenergic receptortarget
DB01224QuetiapineAlpha-1B adrenergic receptortarget
DB01224QuetiapineAlpha-1D adrenergic receptortarget
DB01224QuetiapineAlpha-2A adrenergic receptortarget
DB01224QuetiapineAlpha-2B adrenergic receptortarget
DB01224QuetiapineAlpha-2C adrenergic receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Dtarget
DB01224QuetiapineMuscarinic acetylcholine receptor M1target
DB01224QuetiapineMuscarinic acetylcholine receptor M2target
DB01224QuetiapineMuscarinic acetylcholine receptor M3target
DB01224QuetiapineMuscarinic acetylcholine receptor M4target
DB01224QuetiapineMuscarinic acetylcholine receptor M5target
DB01224Quetiapine5-hydroxytryptamine receptor 1Btarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Etarget
DB01224Quetiapine5-hydroxytryptamine receptor 3Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 6target
DB01224Quetiapine5-hydroxytryptamine receptor 7target
DB01224QuetiapineD(1B) dopamine receptortarget
DB01224QuetiapineD(1A) dopamine receptortarget
DB01224QuetiapineD(3) dopamine receptortarget
DB01224QuetiapineD(4) dopamine receptortarget
DB01224QuetiapineCytochrome P450 3A5enzyme
DB01224QuetiapineCytochrome P450 3A7enzyme
DB01224QuetiapineMultidrug resistance protein 1transporter
DB01224QuetiapineCytochrome P450 2C19enzyme
DB01224QuetiapineCytochrome P450 2D6enzyme